The Joint Commission Recognizes Invuity's® Proprietary Photonics Technology For Improved Patient Safety

Jul 21, 2015, 07:00 ET from Invuity, Inc.

SAN FRANCISCO, July 21, 2015 /PRNewswire/ -- Invuity, Inc., (Nasdaq: IVTY), a leading surgical photonics company, today reported that The Joint Commission has recognized its proprietary photonics technology as an important innovation in the prevention of unintended retained foreign objects (URFOs) that are left inside patients during surgery.

The Joint Commission is the leading hospital accreditation and certification organization in the United States. It recently and independently assessed advanced methods for hospitals to prevent URFOs. In the July 2015 issue of TheSource™: Joint Commission Compliance Strategies, the Commission advised, "Another newer technology to consider is proprietary photonics technology. This provides thermally cool intracavity illumination, which greatly improves visualization of the surgical cavity and allows a thorough visual inspection both during surgery and before closing."1

Invuity's surgical devices incorporate its patented Intelligent Photonics technology, which provides direct visualization of the surgical cavity enabling enhanced precision, efficiency and safety. With improved intracavity illumination, surgeons can better visually inspect the surgical cavity, lowering the chances that objects will be left behind.

The Joint Commission recognized the severity of the URFO problem when it issued its Sentinel Alert No. 51 in October 2013. Sentinel Alerts are the Commission's most critical warning to hospitals and require that they immediately investigate and respond. URFOs are among the most widely reported Sentinel Alerts in the U.S. The medical and liability costs from URFOs exceed $166,000 per incident which may not be reimbursed by the Centers for Medicare & Medicaid Services.2

"Surgeons can reduce the likelihood of URFOs by utilizing superior illumination technology to thoroughly inspect the surgical cavity," said Philip Sawyer, President and CEO of Invuity. "The Joint Commission's acknowledgement of the importance of our proprietary technology in improving patient safety puts Invuity another step closer to becoming the standard of care in surgical procedures."

About Invuity® Invuity, Inc. is a medical technology company focused on developing and marketing advanced photonics devices to improve the ability of surgeons to illuminate and visualize the surgical cavity during open minimally invasive and minimal access surgery. The company's patented Intelligent Photonics™ technology enables enhanced surgical precision, efficiency and safety by providing superior visualization. Clinical applications include breast and thyroid oncology, plastic reconstructive, spine, orthopedic, cardiothoracic and general surgery among others. Invuity is headquartered in San Francisco, CA. For more information, visit www.invuity.com.

1 TheSource™: Joint Commission Compliance Strategies, a Joint Commission publication, Volume 13, Issue 7, July 2015. 2 The Joint Commission's Sentinel Event Alert, Issue 51, "Preventing unintended retained foreign objects" October 17, 2013.

SOURCE Invuity, Inc.



RELATED LINKS

http://www.invuity.com